ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Redesign of the Ferritin Ferroxidase Center for Universal Molecular Binding or Specific Recognition.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Although ferritin, as a versatile nanocarrier, has been engineered to improve cargo loading efficiency for various functions, including therapeutic applications, a universal design strategy enabling tunable molecular binding remains an unmet challenge. This study reports an AI-aided structure-guided engineering approach targeting the ferroxidase center of recombinant human heavy-chain ferritin (rHuHF), aiming to achieve either universal molecular binding or high-affinity specific recognition. Through site-directed mutagenesis of key residues within and flanking the ferroxidase center, two rHuHF variants (rHuHF-C1 and rHuHF-C2) were generated. X-ray crystallographic analysis revealed that the engineered pocket within rHuHF-C2 can accommodate a broad range of hydrophobic molecules (e.g., Curcumin, CUR) via hydrophobic interactions, thus validating their universal molecular binding capability. On the other hand, leveraging AI-assisted rational design, a variant (rHuHF-71) was subsequently engineered to specifically bind CUR with enhanced affinity, facilitated by the formation of hydrogen bonds and optimized hydrophobic contacts. This work establishes a generalizable strategy, designated as "Excavation, Rebuilding, and Validation", for engineering ferritin nanocages with tunable binding specificities, which holds great promise for advancing the development of protein-based drug delivery systems and the design of small-molecule binding proteins.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.